Celgene acquires Delinia, beats on Q4 earnings

Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results.

The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth of 17% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Celgene acquires Delinia, beats on Q4 earnings appeared first on MassDevice.

from MassDevice http://ift.tt/2kaokkE